Merus Labs International Inc. (NASDAQ:MSLI) has earned a consensus recommendation of “Hold” from the twelve ratings firms that are covering the stock. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $4.44.

A number of equities analysts have issued reports on MSLI shares. Canaccord Genuity restated a “buy” rating on shares of Merus Labs International in a report on Friday, August 12th. Zacks Investment Research upgraded Merus Labs International from a “strong sell” rating to a “hold” rating in a report on Thursday, July 14th. Finally, Paradigm Capital restated a “hold” rating and set a $1.60 price target (down from $1.75) on shares of Merus Labs International in a report on Wednesday, October 5th.

Shares of Merus Labs International (NASDAQ:MSLI) traded up 1.24% during trading on Thursday, reaching $0.97. 12,450 shares of the company were exchanged. The company’s market capitalization is $113.49 million. Merus Labs International has a one year low of $0.92 and a one year high of $1.90. The firm’s 50 day moving average price is $1.00 and its 200 day moving average price is $1.25.

Merus Labs International (NASDAQ:MSLI) last posted its quarterly earnings results on Monday, August 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by $0.03. Merus Labs International had a negative return on equity of 3.41% and a negative net margin of 12.89%. Equities research analysts forecast that Merus Labs International will post ($0.07) earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. 1832 Asset Management L.P. raised its stake in shares of Merus Labs International by 6.9% in the first quarter. 1832 Asset Management L.P. now owns 9,767,818 shares of the company’s stock valued at $23,969,000 after buying an additional 627,200 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Merus Labs International by 48.3% in the second quarter. Acadian Asset Management LLC now owns 4,686,382 shares of the company’s stock worth $5,956,000 after buying an additional 1,526,200 shares during the period. I.G. Investment Management LTD. increased its stake in shares of Merus Labs International by 58.9% in the second quarter. I.G. Investment Management LTD. now owns 1,655,500 shares of the company’s stock worth $2,115,000 after buying an additional 613,500 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its stake in shares of Merus Labs International by 68.4% in the second quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 1,352,981 shares of the company’s stock worth $2,232,000 after buying an additional 549,530 shares during the period. Finally, Guardian Capital LP increased its stake in shares of Merus Labs International by 21.1% in the second quarter. Guardian Capital LP now owns 1,208,400 shares of the company’s stock worth $1,533,000 after buying an additional 210,500 shares during the period. 25.73% of the stock is owned by institutional investors and hedge funds.

About Merus Labs International

Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.

5 Day Chart for NASDAQ:MSLI

Receive News & Stock Ratings for Merus Labs International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc. and related stocks with our FREE daily email newsletter.